Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform

Autor: Hiu-Fung Yuen, Kwok Wah Chan, Chee-Wai Chua, Yong-Chuan Wong, Yung-Tuen Chiu, Xianghong Wang, Kwan Man, Ming-Tat Ling
Rok vydání: 2009
Předmět:
musculoskeletal diseases
Male
Cancer Research
medicine.medical_specialty
Cell
Down-Regulation
Antineoplastic Agents
Core Binding Factor Alpha 1 Subunit
Metastasis
Prostate cancer
stomatognathic system
Sphingosine
Internal medicine
medicine
Tumor Cells
Cultured
Gene silencing
Humans
Neoplasm Invasiveness
Neoplasm Metastasis
Protein kinase B
Aged
Regulation of gene expression
Aged
80 and over
Prostatic Intraepithelial Neoplasia
business.industry
Cadherin
Fingolimod Hydrochloride
musculoskeletal
neural
and ocular physiology
Cancer
Prostatic Neoplasms
Middle Aged
musculoskeletal system
medicine.disease
Gene Expression Regulation
Neoplastic
Endocrinology
medicine.anatomical_structure
Oncology
Drug Resistance
Neoplasm
Propylene Glycols
Case-Control Studies
embryonic structures
Cancer research
Androgens
Drug Screening Assays
Antitumor
business
Zdroj: Clinical cancer research : an official journal of the American Association for Cancer Research. 15(13)
ISSN: 1557-3265
Popis: Purpose: Previously, FTY720 was found to possess potent anticancer effects on various types of cancer. In the present study, we aimed to first verify the role of Runx2 in prostate cancer progression and metastasis, and, subsequently, assessed if FTY720 could modulate Runx2 expression, thus interfering downstream events regulated by this protein. Experimental Design: First, the association between Runx2 and prostate cancer progression was assessed using localized prostate cancer specimens and mechanistic investigation of Runx2-induced cancer aggressiveness was then carried out. Subsequently, the effect of FTY720 on Runx2 expression and transcriptional activity was investigated using PC-3 cells, which highly expressed Runx2 protein. Last, the involvement of Runx2 in FTY720-induced anticancer effects was evaluated by modulating Runx2 expression in various prostate cancer cell lines. Results: Runx2 nuclear expression was found to be up-regulated in prostate cancer and its expression could be used as a predictor of metastasis in prostate cancer. Further mechanistic studies indicated that Runx2 accelerated prostate cancer aggressiveness through promotion of cadherin switching, invasion toward collagen I, and Akt activation. Subsequently, we found that FTY720 treatment down-regulated Runx2 expression and its transcriptional activity, as well as inhibited its regulated downstream events. More importantly, silencing Runx2 in PC-3 enhanced FTY720-induced anticancer effects as well as cell viability inhibition, whereas overexpressing Runx2 in 22Rv1 that expressed very low endogenous Runx2 protein conferred resistance in the same events. Conclusion: This study provided a novel mechanism for the anticancer effect of FTY720 on advanced prostate cancer, thus highlighting the therapeutic potential of this drug in treating this disease.
Databáze: OpenAIRE
Externí odkaz: